Page last updated: 2024-12-06

ilmofosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Ilmofosine is a synthetic nucleoside analog that has shown promise as an anticancer agent. It is a derivative of deoxyadenosine, with a modification at the 5' position. Ilmofosine inhibits DNA synthesis and cell proliferation, and it has been shown to be effective against various types of cancer, including leukemia, lymphoma, and solid tumors. The mechanism of action of ilmofosine is thought to involve its incorporation into DNA, leading to the termination of DNA chain elongation and the induction of apoptosis. Ilmofosine is currently under investigation in clinical trials for the treatment of cancer, and it is considered a potential new drug for the treatment of hematologic malignancies.'

ilmofosine: used in treatment of colonic adenocarcinoma in rats; structure given in first source; RN given refers to hydroxide inner salt [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID55008
CHEMBL ID28930
SCHEMBL ID48829
MeSH IDM0127485

Synonyms (46)

Synonym
nsc-601679
nsc601679
ilmofosine
bm-41440
ilmofosine, >=97% (nmr), semisolid (waxy)
brn 4767637
3,5-dioxa-9-thia-4-phosphapentacosan-1-aminium, 4-hydroxy-7-(methoxymethyl)-n,n,n-trimethyl-, (2s-(1(r*(r*)),2alpha,3abeta,7abeta))-
ilmofosina [spanish]
3,5-dioxa-9-thia-4-phosphapentacosan-1-aminium, 4-hydroxy-7-(methoxymethyl)-n,n,n-trimethyl-,hydroxide, inner salt, 4-oxide
bm 41.440
ilmofosinum [latin]
1-hexadecylthio-2-methoxymethyl-rac-glycero-3-phosphocholine
ilmofosine [usan]
D04504
ilmofosine (usan/inn)
83519-04-4
NCGC00165808-01
ilmofosine [usan:inn]
thio alp
CHEMBL28930
bm-41.440
[2-(hexadecylsulfanylmethyl)-3-methoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(+-)-ilmofosine
5zzk34mc3v ,
sh-mm-lysolecithin
bm 41440
ilmofosina
unii-5zzk34mc3v
ilmofosinum
cas-83519-04-4
dtxcid7028934
dtxsid2049008 ,
tox21_113506
1-hexadecylmercapto-2-methoxymethyl-3-propyl phosphoric acid monocholine ester
ilmofosine [inn]
3,5-dioxa-9-thia-4-phosphapentacosan-1-aminium, 4-hydroxy-7-(methoxymethyl)-n,n,n-trimethyl-, inner salt, 4-oxide
3,5-dioxa-9-thia-4-phosphapentacosan-1-aminium, 4-hydroxy-7-(methoxymethyl)-n,n,n-trimethyl-, hydroxide, inner salt, 4-oxide, (+/-)-
89315-55-9
(+/-)-ilmofosine
choline hydroxide, (+/-)-3-(hexadecylthio)-2-(methoxymethyl)propyl hydrogen phosphate, inner salt
ilmofosine [mart.]
SCHEMBL48829
3-(hexadecylthio)-2-(methoxymethyl)propyl 2-(trimethylammonio)ethyl phosphate
3-(hexadecylthio)-2-(methoxymethyl)propyl (2-(trimethylammonio)ethyl) phosphate
Q27263125
STARBLD0005535

Research Excerpts

Overview

Immofosine is a cytostatic/cytotoxic thioether phospholipid derivative.

ExcerptReferenceRelevance
"Ilmofosine is a cytostatic/cytotoxic thioether phospholipid derivative. "( In vivo antitumor activity of ilmofosine.
Bicker, U; Herrmann, DB; Opitz, HG; Pahlke, W, 1990
)
2.01

Treatment

ExcerptReferenceRelevance
"Ilmofosine treated CA46 cells failed to accumulate hyperphosphorylated-cdc2/cyclin B1 complexes that are observed when G2-arrest is induced by either nitrogen mustard or ionizing radiation."( The protein kinase C inhibitor ilmofosine (BM 41 440) arrests cells in G2 phase and suppresses CDC2 kinase activation through a mechanism different from that of DNA damaging agents.
Grunicke, H; Hofmann, J; Jackman, J; Kohn, KW; O'Connor, PM; Schubert, C; Ueberall, F, 1994
)
1.3

Toxicity

ExcerptReferenceRelevance
" CP-46,665 was the most toxic compound, but did not reveal significant differences between nonneoplastic bone marrow and leukemic cells when added in concentrations greater than 1 microgram/ml."( Cytotoxic effects of ether lipids and derivatives in human nonneoplastic bone marrow cells and leukemic cells in vitro.
Berdel, WE; Eibl, H; Fink, U; Fromm, M; Jehn, U; Rastetter, J; Reichert, A; Schick, HD; Ulm, K; Unger, C, 1987
)
0.27
"440 proved to be toxic against cells of two neuroblastoma cell lines in a dose- and time-dependent manner."( Cytotoxicity of ether phospholipid BM 41.440 on neuroblastoma cells.
Bock, I; Bruchelt, G; Girgert, R; Narr, R; Schweizer, P, 1995
)
0.29

Pharmacokinetics

ExcerptReferenceRelevance
" A terminal half-life of ca."( Pharmacokinetics of the thioether phospholipid analogue BM 41.440 in rats.
Besenfelder, E; Bicker, U; Böhm, E; Herrmann, DB; Pahlke, W, 1987
)
0.27
" The relatively long half-life of ilmofosine and its active metabolite support the use of this intermittent schedule."( Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors.
Derry, C; Giantonio, BJ; McAleer, C; McPhillips, JJ; O'Dwyer, PJ, 2004
)
0.84

Compound-Compound Interactions

ExcerptReferenceRelevance
" In this study the interaction of the ALP Ilmofosine in combination with radiotherapy was tested in vitro using the colony forming assay."( [Cytotoxicity of lipid ether ilmofosine in combination with radiotherapy in vitro].
Borchardt, D; Kissler, M; Lichtinghagen, R; Neumann, HA, 1991
)
0.84

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The drug was administered orally as a tablet at a dosage of 150-300 mg/day (75 mg/tablet)."( Treatment results of the thioether lipid ilmofosine in patients with malignant tumours.
Berges, W; Ebeling, K; Hottenrott, G; Mechl, Z; Schlimok, G; Scholten, T; Sterz, R; Strohmeyer, G; Westerhausen, M; Winkelmann, M, 1992
)
0.55
" Cytostatic and cytotoxic effects of TLP were dependent on dosage and incubation time."( Antineoplastic activity of the thioether lysophospholipid derivative BM 41.440 in vitro.
Berdel, WE; Bicker, U; Fink, U; Fromm, M; Pahlke, W; Rastetter, J; Reichert, A; Schick, HD, 1987
)
0.27
" In B16F1 and B16F10 cultures the dose-response curve was not affected by the number of cells/well, while in B16BL6 no more than 20% of the cells were killed at all cell densities measured."( Effect of cell density on cytotoxicity of ether lipid analogues in variants of B16 murine melanoma.
Magistrelli, A; Salmona, M; Tacconi, MT; Trulla, LL, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency27.01050.000221.22318,912.5098AID743035; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency22.61420.000214.376460.0339AID720691; AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency19.23890.000229.305416,493.5996AID743069; AID743075; AID743078
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency16.78550.001723.839378.1014AID743083
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency21.92430.000323.4451159.6830AID743065; AID743066; AID743067
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency13.33320.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency13.33320.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID486216Inhibition of rat RBL2H3 cell granulation assessed as reduction of beta hexasaminidase release at 10 uM2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Computational screening for membrane-directed inhibitors of mast cell activation.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID101567Inhibition of proliferation of breast adenocarcinoma cell line MCF-71997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Enantioselective synthesis and antiproliferative properties of an ilmofosine analog, 2'-(trimethylammonio)ethyl 3-(hexadecyloxy)-2-(methoxymethyl)propyl phosphate, on epithelial cancer cell growth.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID486213Inhibition of rat RBL2H3 cell granulation assessed as reduction of beta hexasaminidase release2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Computational screening for membrane-directed inhibitors of mast cell activation.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID486214Toxicity in rat RBL2H3 cells2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Computational screening for membrane-directed inhibitors of mast cell activation.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID7711Inhibition of large cell lung carcinoma (A427)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Enantioselective synthesis and antiproliferative properties of an ilmofosine analog, 2'-(trimethylammonio)ethyl 3-(hexadecyloxy)-2-(methoxymethyl)propyl phosphate, on epithelial cancer cell growth.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID8678Inhibition of non-small-cell lung adenocarcinoma (A549)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Enantioselective synthesis and antiproliferative properties of an ilmofosine analog, 2'-(trimethylammonio)ethyl 3-(hexadecyloxy)-2-(methoxymethyl)propyl phosphate, on epithelial cancer cell growth.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (58)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (31.03)18.7374
1990's27 (46.55)18.2507
2000's8 (13.79)29.6817
2010's2 (3.45)24.3611
2020's3 (5.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (8.20%)5.53%
Reviews3 (4.92%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other53 (86.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]